Machine signal
Active cluster sell — 4 distinct insiders, $1M, window ends Aug 19, 2026.
Figures computed from official regulatory filings — .
Analysttarget 33.14 USD (+38%) · consensus 4.67/5 · 11 buy · 1 hold · 0 sell
Ownershipinsiders 2.12% · institutions 38.49% · short 6.5% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Zai Lab Ltd only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
8 buys271 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Chen Yajing | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Chen Yajing | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Chen Yajing | Other | $8K | SEC |
| Chen Yajing | Sell | $7K | SEC |
| Chen Yajing | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Chen Yajing | Other | $11.1K | SEC |
| Chen Yajing | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Chen Yajing | Sell | $15.5K | SEC |
| Lis William | Sell | $212.7K | SEC |
| GAYNOR RICHARD | Buy | $33.1K | conv 34 | SEC |
| Du Ying | Other | $83.1K | SEC |
| Du Ying | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Du Ying | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Du Ying | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Du Ying | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Du Ying | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Du Ying | Other | $135.6K | SEC |
| Du Ying | Sell | $130.2K | SEC |
| Du Ying | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Du Ying | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Edmondson Frazor Titus III | Sell | $71.6K | SEC |
| Chen Yajing | Sell | $39.5K | SEC |
| Du Ying | Sell | $428.5K | SEC |
| Edmondson Frazor Titus III | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Du Ying | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |